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Growth of numerous cancer types is believed to be driven by a subpopulation of poorly differentiated cells, often
referred to as cancer stem cells (CSCs), that have the capacity for self-renewal, tumor initiation, and generation of
nontumorigenic progeny. Despite their potentially key role in tumor establishment and maintenance, the energy
requirements of these cells and the mechanisms that regulate their energy production are unknown. Here, we
show that the oncofetal insulin-like growth factor 2 mRNA-binding protein 2 (IMP2, IGF2BP2) regulates oxidative
phosphorylation (OXPHOS) in primary glioblastoma (GBM) sphere cultures (gliomaspheres), an established in
vitro model for CSC expansion. We demonstrate that IMP2 binds several mRNAs that encode mitochondrial
respiratory chain complex subunits and that it interacts with complex I (NADH:ubiquinone oxidoreductase)
proteins. Depletion of IMP2 in gliomaspheres decreases their oxygen consumption rate and both complex I and
complex IV activity that results in impaired clonogenicity in vitro and tumorigenicity in vivo. Importantly,
inhibition of OXPHOS but not of glycolysis abolishes GBM cell clonogenicity. Our observations suggest that
gliomaspheres depend on OXPHOS for their energy production and survival and that IMP2 expression provides
a key mechanism to ensure OXPHOS maintenance by delivering respiratory chain subunit-encoding mRNAs to
mitochondria and contributing to complex I and complex IV assembly.
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A growing number of malignancies are recognized to be
composed of phenotypically heterogeneous cells that
are hierarchically organized and have diverse degrees of
differentiating, proliferative, and tumorigenic capacity
(Frank et al. 2010; Clevers 2011; Magee et al. 2012). The
apex of the hierarchy is believed to be occupied by un-
differentiated cells that can self-renew, give rise to rapidly
proliferating cell subpopulations, and reconstitute a phe-
nocopy of the primary tumor upon injection into immu-
nocompromised mice—properties that have earned them
the denomination of cancer stem cells (CSCs). Despite
being presumed to constitute the key cell subpopulation
that determines tumor development, CSCs are function-
ally defined on the basis of no more than a handful of
properties, chief among which are their ability to initiate
tumor growth and give rise to all tumor cell subpopula-
tions in vivo as assessed by xenotransplantation assays.
Resistance to therapy is often attributed to CSCs but does
not constitute a defining trait (Dean et al. 2005). A major
challenge to the isolation of CSCs from solid tumors is
the paucity of reliable means to identify them. Whereas
the cell surface receptors CD34 and CD38 have helped
define leukemia stem cells based on their convincing
validation as markers of normal hematopoietic stem cells
(Lapidot et al. 1994), the developmental hierarchy of most
tissues that develop solid tumors is insufficiently char-
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acterized to provide a robust basis for CSC identification.
Several single cell surface receptors, including CD133,
CD44, and SSEA, or combinations thereof, have been
used to identify CSCs in glioblastoma (GBM) based on
their expression in subpopulations of cells with self-
renewal and tumor-initiating properties (Singh et al.
2004; Son et al. 2009; Anido et al. 2010). These receptors
have proved to be valid markers of CSCs in freshly re-
moved tumors, but it remains critical to complement
any marker used by stringent functional experiments to
identify cells with high tumor-initiating potential whose
study is essential for better understanding of tumor
development.
Single cells with self-renewing and tumor-initiating
capacity from a variety of solid tumors are able to form
spheres upon in vitro culture under defined serum-free
conditions (Galli et al. 2004; Ricci-Vitiani et al. 2007).
GBM spheres (gliomaspheres) have been shown to allow
long-term expansion of cells with clonogenic and highly
tumorigenic properties that recapitulate the morphology
and genetic mutations of the parental tumor (Lee et al.
2006; Wakimoto et al. 2012). They therefore appear to be
enriched in cells that correspond to the current func-
tional definition of CSCs and represent a reproducible
functional model to address CSC properties.
Because CSCs may, in some cases, display plasticity
that is typically associated with developing tissues, onco-
fetal proteins may participate in and potentially even
determine many of their phenotypic and functional fea-
tures. The oncofetal protein Imp2 (insulin-like growth
factor 2 mRNA-binding protein 2) is expressed in the
developing mammalian brain, suggesting possible impli-
cation in normal embryonic development (Christiansen
et al. 2009). Imp2 belongs to the Imp family of proteins
that regulate subcellular mRNA localization, translation,
and stability (Christiansen et al. 2009) and consists of
three pairs of RNA-binding domains: RRM1–2, KH1–2,
and KH3–4. Studies on paralog proteins IMP1 and IMP3
have shown a correlation between their expression and
poor outcome in various malignancies, including mela-
noma, ovarian cancer, and pancreatic, prostate, thyroid,
breast, and colon carcinoma (Yaniv and Yisraeli 2002;
Himoto et al. 2005a,b; Dimitriadis et al. 2007; Kobel et al.
2007), but mechanisms that underlie their functional
implication in tumor biology have not been identified
so far. Recent evidence suggests that Imp2 may be
implicated in type 2 diabetes (Saxena et al. 2007; Scott
et al. 2007; Christiansen et al. 2009) and in regulating
smooth muscle cell adhesion and motility (Boudoukha
et al. 2010), but with the exception of its expression in
diverse malignancies (Hammer et al. 2005; Himoto et al.
2005b), virtually nothing is known about its role in cancer.
Because of its expression in the developing brain, we chose
to address its possible functional role in GBM.
GBM (grade IV astrocytoma) is among the most malig-
nant forms of brain tumor, with notorious resistance to
conventional anti-cancer therapy. On average, patients
with GBM survive for no more than 1 year following
diagnosis (Louis 2006). Cells that fulfill the currently
accepted functional CSC criteria have been isolated from
GBM based on their expression of diverse cell surface
markers, including CD133 (Singh et al. 2004), SSEA1 (Son
et al. 2009), and CD44 (Anido et al. 2010). Moreover, single
self-renewing GBM cells form gliomaspheres in culture
that display properties consistent with CSC enrichment
(Lee et al. 2006; Wakimoto et al. 2009, 2012). GBM thus
provides a suitable solid tumor model to investigate CSC
properties that distinguish them from cells that comprise
the tumor bulk. We therefore addressed Imp2 expression,
the repertoire of its target mRNAs, and its functional
relevance in GBM. Our observations show that Imp2 is
expressed in GBM and that its expression is highest in
CD133+ cells from freshly isolated tumors, in gliomasphere
cultures in vitro, and in cells associated with blood vessels
and necrotic areas in vivo, where CSCs are believed to
reside.We also demonstrate that Imp2 bindsmitochondrial
respiratory complex IV (CIV) mRNAs and complex I (CI)
proteins and participates in their assembly and function,
thereby regulating oxidative phosphorylation (OXPHOS).
Remarkably, Imp2 expression is shown not only to main-
tain OXPHOS in tumor cells, but to be required for the
survival and function of cells that display self-renewal and
tumor-initiating properties. Our observations define a new
function for Imp2 that may constitute a therapeutic target
in one of the most malignant human tumors.
Results
Imp2 expression in normal brain and glial tumors
Immunohistochemical staining of a normal adult brain
and a panel of gliomas of varying grades revealed that Imp2
is absent in normal brains and grade II and III astrocytomas
(Fig. 1A), whereas 40 out of 51 GBM samples were Imp2-
positive. Correlation between Imp2 expression and glioma
grading was confirmed by microarray analysis of Imp2
expression in an independent data set of 153 gliomas of
different grades and 23 normal samples (Fig. 1B; Sun et al.
2006). Some variability in Imp2 expression is observed
among GBM subtypes, as defined according to The Cancer
Genome Atlas (TCGA) database (http://cancergenome.
nih.gov), with the lowest levels found in the neural sub-
type (Fig. 1C). Interestingly, elevated Imp2 expression
correlates with poor prognosis in the proneural GBM
subtype (Fig. 1D), the molecular subgroup that is the most
refractory to current therapy (Verhaak et al. 2010). No
prognostic significance of Imp2 was observed in other
GBM subtypes (data not shown).
Closer examination of GBM tissue sections revealed
that Imp2 is weakly expressed throughout the tumors,
but that cells that display the strongest reactivity to anti-
Imp2 antibody localize primarily around blood vessels
and hypoxic areas bordering tumor necrosis (Fig. 1A).
Both locations have been shown to be enriched in CSCs
(Li et al. 2009; Anido et al. 2010; Charles et al. 2010). To
determine Imp2 expression in cells that correspond to
GBM CSCs, we performed quantitative real-time PCR
(qRT–PCR) analysis of RNA extracted from freshly sorted
primary GBM cells that had not been subjected to in vitro
culture. We used CD133 expression to identify cells with
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CSC features, given that CD133 has been shown to be
a reliable marker of freshly removed self-renewing and
tumorigenic GBM cells (Singh et al. 2004; Bao et al. 2006).
Threefold higher Imp transcript expression was observed
in CD133+ than in CD133 populations (Fig. 1E, left), and
expression of Imp2 protein was correspondingly higher in
CD133+ cells, as assessed by Western blot analysis using
an anti-Imp2 antibody (Fig. 1E, right). Imp2was also shown
to be expressed in GBM cells bearing the stem/progenitor
cell markers SSEA1 (Supplemental Fig. 1A) and nestin (Fig.
1F) by immunofluorescence costaining in situ.
To determine whether Imp2 is present in normal tissue
stem cells, Imp2 expression in nestin- and GFAP-positive
neural progenitors in a 20th-week human fetal brain was
assessed by immunohistochemistry. These cells are lo-
calized in the subventricular zone (SVZ) and were found
to express Imp2 (Fig. 1G; Supplemental Fig. 1B). Impor-
tantly, Imp2 expression, as assessed by immunohisto-
chemistry, was not detected in other areas of the brain
(Supplemental Fig. 1C), suggesting a functional role that,
in the CNS, may be restricted to stem cells. Imp2 expres-
sion was also assessed by Western blot analysis in the
Figure 1. Imp2 expression in GBM. (A, top panel) Imp2-positive cells in GBM localize predominantly to perinecrotic areas (N) and in
the vicinity of blood vessels (denoted by asterisks). (Bottom panel) Immunohistochemical staining of paraffin GBM sections shows the
absence of Imp2 expression in normal brains and grade II and III astrocytomas. (B) Imp2 expression in astrocytomas of different grades in
an independent data set (Sun et al. 2006); t-test P-values: GBM versus normal brain: P = 9.678 3 1011; GBM versus grade II/III
astrocytoma: P = 4.310 3 105. Whiskers represent the 95th percentile. (C) IMP2 expression differs significantly among TCGA
molecular subtypes (Kruskal-Wallis test P-value < 107) (Verhaak et al. 2010). (D) Kaplan-Meier survival curves for proneural TCGA
samples with ‘‘high’’ or ‘‘low’’ IMP2 expression (see the Materials and Methods). Median survival of the ‘‘Imp2 high’’ group is 13.3 mo
compared with 24.9 for patients in the ‘‘Imp2 low’’ group; log-rank test P-value <0.06. (E) Imp2 expression in GBM CD133+ cells. (Left
panel) Cells from two surgical biopsies of GBM patients were sorted for CD133 expression. Imp2 transcripts as measured by qRT–PCR
were significantly higher in CD133+ populations. (****) P < 0.0001 (unpaired two-tailed t-test). (Right panel) Higher level of Imp2
protein expression in freshly isolated CD133+ cells was confirmed by Western blot analysis. (F) Imp2 expression in GBM CSCs in situ.
Double immunofluorescence staining shows that GBM cells expressing nestin are also positive for Imp2. (G) Costaining of Imp2 and
stem/progenitor cell marker nestin in the SVZ of fetal brains.
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validated neural progenitor cell line hNP1 and shown to
be comparable with that in spherogenic GBM cells (Sup-
plemental Fig. 1D).
To further investigate Imp2 expression in GBM cell
subpopulations, we established primary tumor culture
conditions that favor CSCmaintenance (Galli et al. 2004;
Clement et al. 2007). Cells grown under these conditions
displayed both self-renewal and sphere-forming capacity
in vitro, as well as tumorigenicity in vivo, consistent with
CSC enrichment as defined by current criteria. Exposure
of the spheres to serum resulted in the cells becoming
adherent (Fig. 2A). Flow cytometry analysis revealed that
70% of sphere-forming cells but <1% of adherent cells
were CD133+ (Fig. 2B, top panels). Similarly, 43% of
sphere-forming cells, as opposed to 0.19% of adherent
cells, expressed SSEA1 (Fig. 2B, bottom panels).
Spheres and adherent human GBM cells from three
independent tumors (BT1–3) were compared for tumori-
genicity upon orthotopic injection into immunocompro-
mised mice. Although injection of 50 or 100 spherogenic
cells was not sufficient to initiate tumor growth, as few as
500 sphere-derived cells formed tumors that led to the
death of 100% of the animals within 40–60 d. In contrast,
none of the animals injected with as many as 100,000
adherent cells developed tumors (Fig. 2C; data not
shown). These results are consistent with previous work
that compared the tumor-initiating potential of matched
patient-derived GBM cells grown in spherogenic and
Figure 2. Gliomaspheres as a model of GBM CSC-enriched populations. (A) Morphology of sphere-forming and adherent primary GBM
cultures. (B) FACS analysis of CSC-associated marker expression in the two types of primary GBM cultures. Only GBM cultured as
spheres express CD133 (top panel) and SSEA1 (bottom panel). Representative results for one out of three GBM samples are shown. (C)
Survival of mice after intracranial injection of GBM cells cultured as spheres and adherent cells. Five-hundred spherogenic cells (three
independent cell batches, BT1–3) were sufficient to initiate tumor growth, whereas 100,000 adherent cells derived from spheres
exposed to serum (BT-1adh) failed to form tumors (data for BT2–3adh are not shown); injection of 50 or 100 spherogenic cells was
insufficient for tumor growth initiation (data for BT2–3 are not shown); six animals per condition were injected. (D) Immunofluores-
cence staining of a GBM spheroid (nonreconstituted image [top panel] and three-dimensional [3D] reconstruction [middle panel])
compared with adherent GBM cells (bottom panel) shows high Imp2 expression levels in a CSC-enriched sphere. (Green
immunofluorescence) Imp2 staining; (white) Imp2 channel 3D reconstruction (signal above threshold); (blue) DAPI staining. (E)
Imp2 expression in gliomasphere cells sorted for CD133 expression. Imp2 transcripts as measured by qRT–PCR were significantly
higher in CD133+ populations. (***) P = 0.0003 and 0.001 (unpaired two-tailed t-test).
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adherent conditions (Lee et al. 2006; Wakimoto et al.
2009, 2012). Tumors formed by spherogenic cells were
a phenocopy of the primary malignancies they were
derived from (data not shown), which, together with
CD133 and SSEA expression, supports the notion that
spheres are enriched in CSC-like cells (Suva` et al. 2009).
Elevated Imp2 expressionwas observed in gliomaspheres,
as assessed by immunofluorescence (Fig. 2D, top and
middle panels), although anti-Imp2 antibody staining,
albeit less intense, was noted in adherent cells as well
(Fig. 2D, bottom panel). Quantification by qRT–PCR
confirmed twofold to threefold higher Imp2 expression
in gliomaspheres than in adherent cells (Supplemental
Fig. 1E). Moreover, CD133+ GBM sphere-derived cells
maintained twofold to threefold higher Imp2 levels than
their CD133 counterparts (Fig. 2E). Imp2 expression is
therefore more elevated in CSC-enriched GBM cell pop-
ulations but is not restricted to them.
Imp2 is crucial for GBM CSC maintenance
in vitro and in vivo
To assess the functional relevance of Imp2 expression in
GBM, stable repression of Imp2 transcripts using two
distinct specific shRNA sequences was achieved in pri-
mary GBM sphere-derived cells (Fig. 3A). Cells depleted
of Imp2 had markedly impaired spherogenic capacity in
culture (Fig. 3B), and the spheres that were formed had a
smaller diameter than their wild-type counterparts (Fig.
3C), raising the possibility that both viability and pro-
liferation might be affected. Decreased cell viability, as
measured by fluorescence-activated cell sorting (FACS)
analysis of Calcein AM-stained cells, was indeed ob-
served (Fig. 3D), as was impaired proliferation (Fig. 3E).
Inhibition of sphere-forming capacity by Imp2-depleted
cells was verified in clonogenic assays on three indepen-
dent cell batches where single cells were seeded individ-
ually in three 96-well plates per condition and the
number of resulting spheres was scored (Fig. 3F; Supple-
mental Fig. 2A). Propidium iodide staining indicated
that Imp2 depletion does not affect the cell cycle but
diminishes the number of cycling cells by increasing cell
death (Supplemental Fig. 2B). To determine whether the
increase in cell death is due to apoptosis, we assessed
PARP cleavage, caspase-3 activation, and annexin V in
Imp2-depleted cells. Imp2 knockdown did not enhance
PARP cleavage and activation of caspase 3, as assessed
by Western blot analysis (Supplemental Fig. 2C), and no
difference in anti-annexin V antibody staining was ob-
served between Imp2-expressing and Imp2-depleted cells
(data not shown), indicating that Imp2 depletion does not
induce apoptosis in gliomaspheres. To verify that GBM
sphere-forming cells are depleted upon Imp2 knockdown,
we assessed expression of CD133 as well as that of the
stemness genes SOX2,OCT4, andNANOG in viable cells
bearing Imp2 shRNA. A robust decrease in all four tran-
scripts was observed (Fig. 3G).
We next assessed the effect of Imp2 on the tumorigenic
potential in vivo of GBM cells by orthotopic injection of
gliomaspheres, depleted or not depleted of Imp2, into the
brain of nonobese diabetic–severe combined immunode-
ficient (NOD/SCID) mice. Animals receiving sphere-
derived cells depleted of Imp2 survived for nearly twice
as long as mice injected with sphere-derived cells with
unaltered Imp2 levels (Fig. 3H). Immunohistochemical
analysis revealed that the tumors that eventually emerged
in mice that had received Imp2-depleted cells expressed
Imp2 at a level comparable with that of control cell-
derived counterparts (Supplemental Fig. 2D), indicating
that tumor formation results from escapers of Imp2
depletion. These results provide evidence that Imp2 is
required for gliomasphere maintenance and that the
tumorigenic potential of gliomaspheres depends on
Imp2 expression.
Imp2-bound transcripts and proteins
regulate mitochondrial function
To begin to address the putative role of Imp2 in GBM
CSCs, gliomaspheres were used to immunoprecipitate
Imp2 ribonucleoprotein complexes and analyze Imp2-
bound mRNAs on Affymetrix microarrays (RIP [RNA
immunoprecipitation]-ChIP [chromatin immunoprecipi-
tation] analysis). Among 400 transcripts that were bound
by Imp2, a significant overrepresentation of genes impli-
cated in mitochondrial function and OXPHOS was found
(Fig. 4A,B; Supplemental Table 1). Enrichment of a panel
of the transcripts chosen based on their association with
mitochondrial function in the Imp2-bound fraction was
validated by qRT–PCR (Supplemental Fig. 3A). Binding of
the selected transcripts to Imp2 was also elevated in the
neural progenitor cell line hNP1. Interestingly, their
enrichment in the Imp2 RIP fraction from hNP1 cells
was nearly a magnitude higher than in the corresponding
RIP fraction from gliomaspheres (Supplemental Fig. 3B).
To further confirm the specificity of mRNA binding by
Imp2, a proximity ligation assay (PLA) was performed.
GBM cells were transfected with a biotin-labeled RNA
oligomer of the candidate Imp2 target COX7b or of VSV
as a control. Anti-Imp2 and anti-biotin antibodies could
generate a PLA signal only when they recognize sub-
strates whose mutual proximity corresponds to physical
interaction. The signal generated by each pair of labeled
anti-biotin and anti-Imp2 antibodies is visualized as a
single fluorescent spot (Supplemental Fig. 3C, green). The
results clearly indicate binding of COX7b oligo-RNA by
Imp2. Because Imp2 has not been associated with mito-
chondria thus far and because an adequate energy supply
is crucial to tumor cell growth, we addressed the possible
implication of Imp2 in mitochondrial metabolism. De-
pletion of Imp2 decreased the expression of a panel of
Imp2-boundmRNAs that encodemitochondrial proteins,
which supports functional significance of their binding to
Imp2 (Fig. 4C).
In parallel to the assessment of mRNAs bound to Imp2,
we conducted pull-down experiments using an anti-Imp2
antibody to identify putative Imp2-interacting proteins.
Mass spectrometric detection of several subunits of CI of
the mitochondrial respiratory chain in the pull-down
material not only strengthened the evidence that Imp2
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is functionally related to OXPHOS, but suggested at
least two distinct mechanistic links (Fig. 4D). CI cata-
lyzes electron transfer from NADH to ubiquinone and
constitutes the main entry point of electrons into the
respiratory chain (Carroll et al. 2003, 2006; Murray et al.
2003). Two subunits, NADH dehydrogenase (ubiquinone)
iron-sulfur protein 3 (NDUFS3) and iron-sulfur protein 7
(NDUFS7), which form part of the peripheral arm of
the complex (Fernandez-Vizarra et al. 2009), as well as
NADH dehydrogenase (ubiquinone) 1a complex assem-
bly factor 3 (NDUF3), were identified in the Imp2 pull-
down. The interaction between Imp2 and NDUFS3 was
verified by immunoprecipitation and Western blot
analysis (Fig. 4E). Moreover, protein expression levels
of CI subunits identified in the pull-down experiment
decreased upon Imp2 knockdown (Fig. 4F,G), sup-
porting the functional relevance of Imp2–CI subunit
interactions.
Figure 3. Effect of Imp2 depletion on gliomasphere cells. (A) Imp2 silencing in gliomasphere cells stably expressing two different
shRNAs. (B) Morphology of spheres formed by control shRNA-expressing and Imp2-depleted GBM cells in culture. (C) Sphere
morphology change upon Imp2 depletion shown as sphere diameter. P < 0.0001 (n = 50), unpaired two-tailed t-test. Whiskers represent
the 95th percentile. (D) Cell viability as measured by FACS analysis of Calcein AM staining in three different cell batches. Bars
represent the percentage of positively stained cells. Low viability of ctrl cells is due to puromycin selection. (**) P = 0.0094 and 0.0068,
respectively; paired two-tailed t-test. Error bars represent the standard deviation (SD). (E) Cell proliferation in spherogenic culture
conditions upon Imp2 knockdown as assessed by BrdU incorporation. (***) P = 0.0008 and 0.0007; (**) P = 0.0024, 0.0057, 0.002, and
0.0027, respectively; unpaired two-tailed t-test. Error bars represent the SD. (F) Single-cell clonogenic assay performed on three
independent cell batches; single cells were plated in 96-well plates, and three plates per condition were used; statistical analysis for
each cell batch was performed using unpaired two-tailed t-test comparing control cells with Imp2-depleted cells. (*) P = 0.0227; (**) P =
0.0015; (***) P = 0.0008; error bars represent the SD. (G) Imp2 depletion decreases CD133, SOX2, OCT4, and NANOG transcripts as
measured by qRT–PCR. (*) P = 0.0443; (**) P = 0.0098; (*) P = 0.013; (**) P = 0.0034; (***) P = 0.0002. Representative values from two
independent experiments are shown. (H) Imp2 shRNA expression decreases GBM CSC tumor-forming capacity. The experiment was
repeated using three batches of cells. Six animals were used per condition. The differences between Imp2- and ctrl shRNA-expressing
cells for each cell batch were significant (log-rank [Mantel-Cox] test). P-values for BT-1, BT-2, and BT-3 were 0.0088, 0.0036, and 0.0056,
respectively. The median survival of the animals is presented in the right panel.
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Figure 4. mRNA and proteins bound by Imp2 suggest a functional role in mitochondrial processes. (A) Specificity of the RIP assay is
illustrated in a heat map that compares transcripts obtained by immunoprecipitation using anti-Imp2 and isotype-matched control
antibody; results for three batches of primary GBM cultures in spherogenic conditions are shown. (B) Gene ontology (GO) analysis of
Imp2-bound mRNA shows enrichment in transcripts associated with mitochondrial function. A GO term was considered over-
represented if the nominal P of the exact one-tailed Fisher test was <105. The length of the bar for each term is proportional to the
number of bound mRNAs annotated to the term. The shaded part of the bar represents the number of annotated mRNAs expected by
chance. (C) Imp2 knockdown decreases expression of Imp2-bound transcripts (transcripts associated with mitochondrial functions are
shown). (D) Identification of several mitochondrial respiratory CI proteins by mass spectrometry analysis of anti-Imp2 antibody pull-
down material. (E) Immunoprecipitation of Imp2 followed by Western blotting using an anti-NDUFS3 antibody (top panel) and
immunoprecipitation of NDUFS3 followed by Western blotting using an anti-Imp2 antibody (bottom panel) confirm the interaction
between the two proteins. (Ctrl) Immunoprecipitation with isotype-matched control antibody; (PB) post-beads unbound fraction. (F)
Imp2 depletion decreases the level of Imp2-bound proteins. (G) Densitometric quantification of the Imp2-bound proteins observed in F.
Data were normalized to actin.
Depletion of Imp2 impairs OXPHOS in gliomaspheres
Because Imp2-bound transcripts and proteins are required
for OXPHOS, we investigated the effect of Imp2 depletion
on the mitochondrial activity of spherogenic GBM cells.
MitoTracker Red staining, which provides an indication
of mitochondrial activity, was significantly decreased in
cells depleted of Imp2 using two distinct shRNA se-
quences (Fig. 5A). MitoTracker Red staining was per-
formed on viable cells following the exclusion of dead
cells by DAPI and Calcein AM staining such that the data
reflect the decreased mitochondrial activity in live cells.
To address possible changes in mitochondrial activity
following Imp2 depletion, oxygen consumption rate (OCR)
and extracellular acidification rate (ECAR) measurements
that reflect OXPHOS and glycolysis, respectively, were
made. These measurements were performed on equal
numbers of viable cells from all three populations imme-
diately after cell counting, thereby excluding cell death
as an explanation for decreased metabolic activity. Cells
expressing either Imp2 shRNA displayed a significantly
decreased OCR (Fig. 5B) but an unaltered ECAR (data not
shown). Normalization for equal viable cell seeding was
performed by collecting cells following oxygen consumption
measurement and staining them with Calcein AM. The
assay was subsequently performed on cells sorted for
CD133+ expression from freshly removed GBM, unex-
posed to in vitro culture, and revealed augmented OCR in
comparison with their CD133 counterparts, suggesting
that CSC marker-bearing subpopulations maintain ele-
vated OXPHOS (Fig. 5C). To determine whether the
changes in the OCR triggered by Imp2 depletion might
reflect an overall decrease in mitochondrial function,
enzymatic activity of the tricarboxylic acid cycle enzyme
citrate synthase was assessed (Fig. 5D), but no significant
decrease in its activity was observed. Decreased OCR in
the face of maintained mitochondrial enzymatic activity
supports the notion that the effect of Imp2 is selective for
OXPHOS. Because all of the observations thus far suggest
Imp2 involvement in the regulation of energy production,
cellular ATP content was measured. A significant de-
crease in ATP was observed in viable sphere-derived cells
devoid of Imp2 (Fig. 5E).
Our observations that Imp2 binds CI proteins and CIV
subunit transcripts and that Imp2 depletion affects both
CI protein and CIVmRNA/protein levels suggest that the
effects of Imp2 depletion may be related to changes in CI
and CIV activity. To address this possibility, we performed
Figure 5. Imp2 depletion affects mitochondrial respiration in gliomasphere cells. (A) MitoTracker Red staining of mitochondria
decreases in cells depleted of Imp2, as analyzed by FACS. DAPI-stained dead cells were excluded from the analysis. Bars represent mean
values for three independent cell batches. (**) P = 0.0071 and 0.0081 (paired two-tailed t-test), respectively. Error bars represent the SD.
(B) OCR is decreased by Imp2 depletion. OCR values were normalized to viable cell counts as assessed by post-measurement FACS
analysis of Calcein AM staining. Results for three cell batches are shown. Imp2 shRNA1: (**) P = 0.005, (*) P = 0.005, (**) P = 0.0038;
Imp2 shRNA2: (*) P = 0.0114, (**) P = 0.0021, (***) P = 0.0004 (unpaired two-tailed t-test). (C) The OCR is higher in freshly isolated
CD133+ than in CD133 cells. Results for two freshly obtained surgical biopsies are shown. (*) P = 0.0355; (****) P < 0.0001 (unpaired
two-tailed t-test). (D) Citrate synthase activity upon Imp2 knockdown. Representative values of two experiments with three different
cell batches are shown. P > 0.05, not significant. (E) ATP content upon Imp2 knockdown. Representative values of two experiments
with two different cell batches are shown. (**) P = 0.0024 (two-tailed t-test). (F) Respiratory CI and CIV activity is lowered by Imp2
knockdown, as shown by BN-PAGE and in-gel activity assay. Forty micrograms of the mitochondrial extracts was loaded onto the gel.
Representative results of three independent experiments with three different cell batches are shown. Coomassie staining shows band
intensity before the activity assay. Error bars represent the SD. (G) Quantification of CI and CIV Coomassie-stained bands. No
significant difference was observed. (H) Quantification of CI and CIV in-gel activity. (***) P = 0.0008; (*) P = 0.0321 (two-tailed t-test).
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a Blue Native PAGE (BN-PAGE) that allows in-gel mea-
surements of respiratory complex activity (Nijtmans
et al. 2002). Mitochondrial extracts from GBM spheres
stably infected with Imp2 shRNA showed a marked
decrease in both CI and CIV activity (Fig. 5F–H).
Mitochondrial respiration generates reactive oxygen
species (ROS), raising the question as to whether the
effect of Imp2 depletion in sphere-forming cells could be
at least partially explained by ROS-induced cell death.
Superoxide anion production measured by MitoSOX
staining was decreased in Imp2-depleted spherogenic cells
(Supplemental Fig. 4A), aswas the level of 4-hydroxynonenal
protein adducts, stable lipid peroxidation products that
reflect chronic oxidative stress (Supplemental Fig. 4B).
These observations suggest that Imp2 depletion-triggered
cell death is not due to increased ROS production.
OXPHOS inhibition by rotenone mimics the effects
of Imp2 depletion and is crucial for energy metabolism
in spherogenic GBM cells
Our observations provide evidence that GBM spheres
require an intact mitochondrial respiratory chain to
survive and sustain their tumorigenic potential. To ad-
dress the relative importance of OXPHOS and anaerobic
glycolysis in GBM spheres, we used inhibitors of each
pathway, including rotenone, which blocks CI activity,
and oxamic acid, which abrogates lactate dehydrogenase.
Rotenone treatment recapitulated the effect of Imp2
shRNA with disruption of sphere morphology (Fig. 6A,B)
and abrogation of clonogenicity (Fig. 6C). In contrast,
oxamic acid mildly increased the number of spheres in
culture, as shown by post-treatment clonogenic assays
(Fig. 6A–C). Inhibition of CI by addition of rotenone to
the cell culture medium during measurement decreased
the OCR of control shRNA-expressing cells to the level
measured in Imp2-deficient cells (Fig. 6D), supporting
the notion that the observed difference in OCR in Imp2-
depleted cells was due to a defect in OXPHOS.
Our observations thus far suggest that despite being
resistant to hypoxia (Li et al. 2009), gliomaspheres heavily
rely on OXPHOS as their main energy-producing path-
way. To determine whether spherogenic and adherent
cells possess different energy requirements, the effects of
OXPHOS and anaerobic glycolysis inhibitors were assessed
on primary spherogenic and adherent GBM cells obtained
by culturing sphere-derived cells in serum-containing
medium to induce differentiation (Singh et al. 2004).
ATP levels measured after short-term treatment with
rotenone were decreased only in gliomaspheres, whereas
adherent cell ATP content was diminished only by oxamic
acid (Fig. 6E). Proliferation assays upon addition of oxamic
acid to the culture medium showed that inhibition of
anaerobic glycolysis affects the growth of serum-treated
GBMcells but not sphere-forming cells (Fig. 6F). In contrast,
rotenone decreased proliferation of both cell types. Inhibi-
tion of respiratory CI by rotenone may not only decrease
ATP levels in cells dependent on OXPHOS, but may also
generate ROS, leading to induction of cell death. We
therefore tested superoxide production by MitoSOX
staining and ROS-dependent protein oxidation using
HNE adduct assays on spheres and adherent cells treated
with rotenone (Supplemental Fig. 4C,D). Similar to Imp2
depletion (Supplemental Fig. 4A), reduction of oxidative
stress was observed in spherogenic cells exposed to rote-
none. In contrast, rotenone increased superoxide produc-
tion and protein oxidation in adherent cells, which may
reflect enhanced ROS production and explain their de-
creased proliferation in response to rotenone.
ATP-independent inhibition of adherent cell prolifera-
tion after rotenone treatment was confirmed by oligomy-
cin treatment. Oligomycin, which inhibits the ATPase of
respiratory complex V, had no effect on adherent cell
proliferation, whereas it strongly inhibited sphere prolifera-
tion (Supplemental Fig. 4E). This observation supports the
notion that spherogenic and adherent GBM cells that may
represent the tumor bulk have distinct energy requirements.
The metabolic differences between adherent cells and
spheres were also reflected in Imp2 knockdown pheno-
types (Supplemental Fig. 5A–D). Depletion of Imp2 in
adherent cultures did not affect cellular proliferation or
ATP levels, although, similar to spheres, the OCR was
decreased (Supplemental Fig. 4D). To verify that the OCR
was not affected by merely culturing cells as spheres or
adherent monolayers, we assessed the OCR of serum-
treated adherent cells following trypsinization. The OCR
of adherent GBM cells was not observed to change whether
the measurement was made on cells that were allowed to
attach to the culture plate or on cells that had been freshly
resuspended (data not shown). Moreover, analysis of the
mRNA repertoire bound by Imp2 in adherent cells re-
vealed that it was almost identical to that bound to Imp2
in spheres (Supplemental Table 2). It is noteworthy that
the intracellular localization of the Imp2 protein is the
same in spheres and adherent cells (Supplemental Fig. 5E).
To further address the relationship between Imp2 and
mitochondrial respiration, the effect of Imp2 overexpres-
sion in the immortalized astrocytic cell line SVGp12 was
assessed. Introduction of exogenous Imp2 into SVGp12
cells resulted in increased Imp2-interacting protein ex-
pression; enhanced mitochondrial activity, as assessed by
MitoTracker Red staining; and augmented OCR (Sup-
plemental Fig. 6). In addition, a rescue experiment on
spherogenic cells was performed. Sphere-derived cells
overexpressing the coding sequence of Imp2 were tran-
siently transfected with siRNA targeted at the 39 un-
translated region (UTR) of Imp2 mRNA (Supplemental
Fig. 6D). OCR measurement in these cells revealed that
the oxygen consumption decrease caused by Imp2 de-
pletion can be rescued by exogenous reintroduction of the
protein (Supplemental Fig. 6E). Together, these results
support direct involvement of Imp2 in OXPHOS control.
The effect of hypoxia on Imp2 expression and mRNA
binding and the clonogenic potential of
gliomasphere-derived cells
Thus far, our results indicate that gliomasphere mainte-
nance requires OXPHOS. However, CSCs have been
identified in both hypoxic regions and vascular niches
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in primary GBM (Li et al. 2009; Anido et al. 2010; Charles
et al. 2010). We therefore investigated the effect of
hypoxia on Imp2 expression and function. Imp2 protein
expression was assessed in both normoxic and hypoxic as
well as high- and low-glucose culture conditions. None of
these conditions induced a significant variation in Imp2
expression (Supplemental Fig. 7A). Based on our observa-
tions that impairment of OXPHOS by Imp2 depletion
or rotenone treatment in normoxic conditions inhibits
gliomasphere formation, we assessed the effect of both
measures on gliomasphere formation under hypoxic con-
ditions. Neither the effect of Imp2 depletion nor that of
rotenone on sphere-forming capacity was altered by
hypoxia (Supplemental Fig. 7B), suggesting that 1%
oxygen is sufficient for gliomaspheres to maintain
OXPHOS. As expression of Imp2 in hypoxic conditions
remained unchanged, we assessed possible hypoxia-in-
duced alterations in its mRNA-binding ability. qRT–PCR
analysis of Imp2 RIP fractions revealed that several of
the identified Imp2 target mRNAs were more highly
enriched when gliomaspheres were cultured under hyp-
oxic than under normoxic conditions (Supplemental Fig.
7C), suggesting a higher efficacy of mRNA binding by
Imp2 in hypoxia.
Figure 6. Inhibition of OXPHOS impairs clonogenicity and survival of gliomasphere cells. (A) Inhibition of OXPHOS with 1 mM
rotenone affects gliomasphere morphology in the same way as Imp2 silencing. (B) Morphological changes in response to rotenone
(ROT), oxamic acid (OXA), and Imp2 knockdown shown as sphere diameter measurements. (****) P < 0.0001 (n = 50), unpaired two-
tailed t-test. (C) Clonogenic potential of gliomasphere cells is decreased by rotenone treatment. (**) P = 0.0024, unpaired two-tailed
t-test. In contrast, anaerobic glycolysis inhibition by 25 mM oxamic acid does not significantly affect the clonogenic potential of
GBM CSCs. Representative results for one out of three cell batches are shown. (D) Addition of 1 mM rotenone (indicated by the
vertical line) decreases the OCR of control cells to a level comparable with that measured in Imp2-depleted cells. (E) Rotenone
decreases ATP content in spheres but not in adherent cells, whereas oxamic acid affects adherent cells but not spheres. (***) P =
0.0001; (**) P = 0.0074, unpaired two-tailed t-test. Representative results for one out of two cell batches are shown. (F) Oxamic acid
affects proliferation of only adherent cells as measured in a BrdU incorporation assay; rotenone inhibits proliferation of both
gliomasphere and adherent cells. (***) P = 0.0006 (DMSO vs. rotenone in spheres), 0.0008 (DMSO vs. rotenone in adherent cells), and
0.0001 (DMSO vs. oxamic acid in adherent cells), unpaired two-tailed t-test. Representative results for one out of two cell batches are
shown. Error bars represent the SD.
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Imp2 regulates OXPHOS by mRNA delivery
to mitochondrial polysomes and by control
of respiratory CI assembly
The mechanism by which Imp2 controls mitochondrial
energy production could involve stabilization of its target
mRNAs and/or their subcellular localization to the vi-
cinity of mitochondria, in addition to the assembly and
function of CI. To determine whether degradation of its
target mRNAs depends on Imp2 expression, cells over-
expressing or depleted of Imp2 were treated with actino-
mycin D to block mRNA polymerization. Degradation of
selected target transcripts was then assessed at several
time points for a total of 12 h (Fig. 7A). Although the
expression level of the target RNAs was dependent on
that of Imp2, the slope of the decay curve was not
significantly altered, suggesting that Imp2 does not play
a major role in its target mRNA stability. Next, Imp2
localization was assessed by Western blot analysis of
subcellular GBM sphere-forming cell fractions using an
anti-Imp2 antibody. Imp2 was found in the cytoplasm as
well as in intact mitochondria, where NDUFS3 is also
located (Fig. 7B, lane 2). Proteinase K treatment of mito-
chondria abolished Imp2 detection, consistent with its
localization on the mitochondrial surface (Fig. 7B, lane 3).
The partial degradation of NDUFS3 observed following
proteinase K treatment suggests that a fraction of its cel-
lular content is localized on the mitochondrial surface,
where interaction with Imp2 may occur.
NDUFS3 andNDUFS7 both interact with Imp2 and are
found in a subcomplex that initiates CI assembly (Vogel
et al. 2007), suggesting that Imp2 may be implicated in
early CI assembly events. BN-PAGE followed by Western
blot analysis of NDUFS3 in control and Imp2-depleted
cells revealed a decrease in the amount of high-molecular-
weight CI in the latter, together with the appearance of
more prominent lower-molecular-weight bands that
correspond to CI subcomplexes (Fig. 7C, left panel). To
verify that the high-molecular-weight CI depletion was
not merely a reflection of a decrease in NDUFS3 expres-
sion, we assessed the expression of the CI subunit ND2
that does not interact with Imp2. A similar effect was
Figure 7. Imp2 may provide mRNA delivery to
mitochondria and regulate respiratory complex as-
sembly. (A) Imp2 does not play a role in the
stabilization of mRNA that it binds; degradation of
Imp2-bound transcripts was measured by qRT–PCR
0, 4, 8, and 12 h after actinomycin D addition. Lines
represent linear regression; the slopes of the linear
regression are not significantly different between
Imp2-expressing and Imp2-depleted cells. Represen-
tative data from two independent overexpression/
knockdown experiments and for two representative
transcripts are shown. (B) Imp2 localizes to the
surface of mitochondria as illustrated by subcellular
fractionation. (CYT) Cytosolic fraction; (MT) iso-
lated mitochondria. Western blot analysis of Imp2
and NDUFS3 shows the disappearance of the Imp2
band following proteinase K treatment of intact
mitochondria. (C) Assembly of respiratory CI and
CIV is impaired by Imp2 knockdown; BN-PAGE
followed by Western blot (WB) using anti-NDUFS3,
anti-ND2, and anti-COX7b antibodies. Imp2 knock-
down depleted the high-molecular-weight CI
(NDUFS3 WB) and increased accumulation of its
intermediate species (ND2 WB). CIV assembly
(COX7b WB) was also altered. (>) CI holocomplex;
(*) CI subcomplexes containing NDUFS3 (pattern
corresponding to that published by Vogel 2007); (o)
CI subcomplexes containing ND2; (m) monomeric
ND2; (>>) CIV holocomplex; (#) CIV subcomplexes.
Holocomplex band localization was verified with
Native Mark marker (Invitrogen) and the in-gel
activity assays. (D) Imp2 delivers mRNA to mito-
chondria-bound polysomes; qRT–PCR was performed
on a mitochondria-bound polysomal fraction and
cytosolic polysomes isolated from SVGp12 astrocytes
overexpressing Imp2 or infected with empty vector.
Ratios of transcript content in cytosolic to that in mitochondria-bound polysomes are presented. The ratio value for UCP2,
a mitochondria-bound polysome-associated transcript, was set as the 0 value. Values below 0 indicate higher mitochondrial than free
polysome association of a given transcript. Controls were 12S (mitochondrial rRNA for mitochondria purification efficiency), UCP2 (a
mitochondrial protein that is not a direct target of Imp2), and nestin (a cytosolic protein that is not a direct target of Imp2). Representative
values of two independent Imp2 overexpression experiments are shown.
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observed in Imp2-depleted cells, as illustrated by a de-
pletion of high-molecular-weight CI and the appearance
of numerous lower-molecular-weight bands that corre-
spond to CI subcomplexes (Fig. 7C, middle panel). These
observations suggest that CI assembly requires Imp2.
Although much less is known about CIV than about CI
assembly, we observed that COX7b displays markedly
different migration, as assessed by Western blot analysis
of lysates from control and Imp2-depleted cells, consis-
tent with a possible defect in CIV assembly in the latter
(Fig. 7C, right panel).
To determine whether Imp2 may serve as a delivery
system for nuclear-encoded transcripts to mitochondrial
polysomes, subcellular fractionation of extracts from
astrocytes overexpressing Imp2 was performed. Using
qRT–PCR, ratios between transcripts in the cytosolic
and mitochondria-bound polysomal fractions in control
and Imp2-overexpressing cells were calculated. High
Imp2 expression was associated with increased amounts
of Imp2-bound transcripts on mitochondria-bound poly-
somes (Fig. 7D). These results indicate that Imp2 facilitates
localization of nuclear-encoded mRNA to the vicinity of
mitochondria, where subsequent translation and inser-
tion into mitochondrial membranes may occur.
Discussion
Our study provides the novel observations that an mRNA-
binding oncofetal protein, Imp2, controls OXPHOS in
GBM cells by binding both respiratory CIV transcripts
and CI proteins. Imp2may thereby play an essential role in
the survival of cells that use OXPHOS as their primary
energy source.
Imp2 remains the least-studiedmember of its family. In
human tissues, low levels of Imp2 transcripts have been
detected in adult bone marrow, colon, kidney, salivary
glands, small intestine, and gonads (Hammer et al. 2005),
whereas its protein has thus far been reported only in the
islets of Langerhans (Dai et al. 2011) and gonads (Hammer
et al. 2005). In mice, Imp2 is found in a broad range of
adult tissues, its highest expression being observed in the
brain (Dai et al. 2011). Our study shows that Imp2 is
absent in normal adult human brains and primary astro-
cytes (data not shown). However, it was detected in the
SVZs of fetal brains where stem cells reside.
Among GBM molecular subtypes, as defined by the
TCGA database, Imp2 is least expressed in neural GBM,
characterized by a gene expression profile that most
closely resembles normal brain tissue. In contrast, high
Imp2 expression bears a prognostic value for patients
with the proneural GBM subtype whose gene expression
profile resembles that of tumors associated with elevated
CD133 expression (Joo et al. 2008). Moreover, the gene
expression profile of proneural GBM shares similarities
with that of fetal neural stem cells, suggesting that it
may contain an elevated proportion of stem-like cells
(Lottaz et al. 2010). These results are consistent with our
in vitro studies, showing that Imp2 is not exclusively
expressed in CSC-enriched GBM subpopulations, but
that it may play a crucial role in their maintenance.
In the present study, we used gliomasphere cultures
as a model for highly tumorigenic subpopulations that
display self-renewal capability and showed that Imp2-
dependent OXPHOS is required for the maintenance of
these cells. Sphere-derived CD133+ cells displayed higher
oxygen consumption than their CD133 counterparts,
and we further demonstrated that CD133+ cell subpopu-
lations from fresh GBM, unexposed to in vitro culture,
not only express elevated levels of Imp2, but also con-
sume more oxygen than CD133 cells. Although we
could not perform functional assays on ex vivo CD133+
cells without expansion in vitro and could not measure
oxygen consumption of single cells that may have allowed
definitive distinction between CSC and non-CSC popula-
tions, the sum of our observations supports the notion that
Imp2 plays a key role in the survival and function of GBM
cells that display CSC features.
The function of Imp2 as an mRNA-binding protein was
first established with the demonstration that it binds
IGF2 mRNA (Nielsen et al. 1999). Only one report so far
has indicated the existence of other targets by showing
that Imp2 can regulate cytoskeletal reorganization,
which underlies the motility of human fetal myoblasts
(Boudoukha et al. 2010). Interestingly, Imp2-bound tran-
scripts in myoblasts also contain a significant proportion
of species associated with mitochondrial respiration,
suggesting that Imp2may be implicated in cellular energy
production independent of cell type. Another potential
clue that may link Imp2 to mitochondrial functions is
the observation that a single-nucleotide polymorphism
within the IMP2 gene is strongly associated with type 2
diabetes (Saxena et al. 2007; Scott et al. 2007), where
significant mitochondrial dysfunction is known to occur.
Amechanistic link tometabolismwas, in fact, established
by the demonstration that Imp2 is a target of mTOR (Dai
et al. 2011), a kinase complex that is tightly coupled to
cellular bioenergetics (for review, see Zoncu et al. 2011).
mTOR was shown to phosphorylate Imp2, which results
in its increased binding to IGF2 mRNA. Defects in mTOR
regulation have been associated with both cancer and type
2 diabetes, suggesting that part of the effect of aberrant
mTOR pathway activation could potentially be due to
altered Imp2 activity.
Of the multitude of proteins that compose the respira-
tory electron transport chain, only a fraction is encoded
by mitochondrial DNA. The majority are encoded by
nuclear DNA, and their transcripts are presumed to be
transported by RNA-binding proteins to the vicinity of
mitochondria, where they can be translated onmitochon-
dria-bound polysomes and inserted into mitochondrial
membranes (Suissa and Schatz 1982). Our observations
indicate that Imp2 provides at least one vehicle for
mRNA transport to mitochondria. Not only are numer-
ous CIV protein-encoding transcripts bound to Imp2, but
their quantity is augmented in polysomes associated with
mitochondria upon Imp2 overexpression in an astrocytic
cell line. The relevance of Imp2-mediated delivery of
these transcripts is supported by the finding that de-
pletion of Imp2 leads to impaired CIV assembly and loss
of CIV activity. Thus, one hitherto unknown function of
Imp2 in glioblastoma cancer stem cells
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Imp2 is the regulation of respiratory CIV assembly and
function by delivering at least some of its building blocks
to mitochondrial polysomes.
Involvement in mitochondrial functions is further
supported by the observation that Imp2 binds several
proteins of respiratory CI. Unexpectedly, CI subunit-
bound Imp2 was detected on the mitochondrial surface,
suggesting that Imp2 binds CI proteins prior to their
translocation into mitochondria. The interaction may
transiently anchor Imp2 to the mitochondria, possibly
facilitating the delivery and local translation of Imp2-
bound transcripts. Repression of Imp2 resulted in de-
pletion of high-molecular-weight CI bands and impaired
CI function, as assessed by in-gel activity assays. Thus,
the interaction of CI proteins with Imp2 appears to be
required for CI assembly and activity. The absence of
Imp2-bound CI transcripts suggests that Imp2 regulates
CI function by physically interacting with its subunit
components. CI is composed of several subcomplexes,
and its assembly in mammalian cells is a multistep
process that remains incompletely understood (Vogel
et al. 2007). Interestingly, NDUFS3 and NDUFS7, the
subunits of CI bound by Imp2, form the earliest and
smallest subcomplexes, suggesting that Imp2 could be
implicated in the initiation of CI assembly (Vogel et al.
2007). Numerous chaperones are believed to be required
for CI assembly and translocation of its components from
the cytoplasm to the inner mitochondrial membrane, but
only a few have been identified thus far (for review, see
Rehling et al. 2004). Our present observations are consis-
tent with the possibility that Imp2 may be a CI subunit
chaperone that orchestrates CI assembly and/or trans-
location into mitochondria while at the same time de-
livering CIV transcripts. By controlling both CI and CIV
assembly and function, Imp2 may play a prominent role
in the regulation of cellular energy production, and its
expression may therefore be crucial to cells that derive
their energy primarily from OXPHOS.
Gliomasphere dependence on OXPHOS predicts that
GBM CSCs should be located in highly oxygenated
regions of the tumor. Although they indeed primarily
reside in perivascular areas (Calabrese et al. 2007; Currle
and Gilbertson 2008), GBM CSCs are also found in
hypoxic tumor zones (Li et al. 2009). Accordingly, Imp2
expression was elevated in GBM cells around blood
vessels and in pseudopalisading cells surrounding necro-
sis. GBM pseudopalisades are believed to be composed of
cells that migrate away from ineffective or obstructed
vasculature (Rong et al. 2006). It is therefore plausible
that the disruption of blood supply following thrombosis
caused CSCs to leave their primary perivascular niche
and migrate to constitute new niches characterized by
the pseudopalisading phenotype. Consistent with this
notion and the observation that GBM CSCs are resistant
to hypoxia (Ezhilarasan et al. 2007; Li et al. 2009), we
found that Imp2 levels remain constant under normoxic
and hypoxic culture conditions and that hypoxia does not
affect GBM clonogenic potential (Supplemental Fig.
7A,B). Interestingly, target mRNA binding by Imp2 is
enhanced in hypoxic conditions (Supplemental Fig. 7C),
suggesting a possible mechanism for maintaining OXPHOS
in a low-oxygen environment. Active use of OXPHOS by
cancer cells should not be inhibited by hypoxic condi-
tions, as oxygen concentration in a hypoxic microenvi-
ronment has been determined to be in the range of 8–57
mM (Vaupel et al. 1989; Go¨rlach and Acker 1994; Suther-
land 1998), which is 10-fold higher than the limiting
concentration for the O2 dissociation constant for cyto-
chrome c oxidase (Mason et al. 2006). The dependence of
GBM CSC-enriched subpopulations on OXPHOS sug-
gested by our results may thus be independent of their
location within the tumor.
Bioenergetic reprogramming constitutes part of the
profound alterations induced by transformation. The ensu-
ing changes in growth patterns and augmented anabolism
impose increased energy requirements on transformed
cells compared with their normal counterparts (Hanahan
and Weinberg 2011). The longstanding view, first pro-
posed by Warburg (Vander Heiden et al. 2009), is that
these requirements are primarily fulfilled by glycolysis
even in the presence of an adequate oxygen supply.
Glycolysis provides rapid but inefficient energy produc-
tion, generating 2–4 mol of ATP per mole of glucose.
However, glucose, along with glutamine, is the major
source of carbon, free energy, and reducing equivalents
required to support cell growth and division. Thus, a sub-
stantial portion of glucose is likely to be used to generate
macromolecular precursors of fatty acid, nonessential
amino acid, and nucleotide synthesis in proliferating
cells. Nevertheless, glycolysis is not a major energy source
in all cancer cells (Jose et al. 2011), and those that have not
sustained major mitochondrial damage or corresponding
DNA mutations may alternate between OXPHOS and
glycolysis, depending on their state and microenviron-
ment. In our hands, spherogenic GBM cells proliferated
more slowly than their adherent progeny. Such slowly
proliferating cells may use the more efficient OXPHOS
pathway that yields 36 mol of ATP per mole of glucose.
Oxygen supply, required for OXPHOS, may be more
readily available for GBM CSCs than for more differenti-
ated GBMcells, based on the observations that GBMCSCs
reside in the proximity of blood vessels (Calabrese et al.
2007; Currle and Gilbertson 2008) and that they may even
generate tumor endothelium (Ricci-Vitiani et al. 2010;
Wang et al. 2010). As CSC progeny proliferate, increased
anabolic requirements and/or genetic mutations that in-
activate mitochondria could force the cells to switch to
a predominantly glycolytic metabolism. It is therefore
plausible that hierarchical cellular organization within
a tumor is also reflected in metabolic differences between
cancer cell subpopulations.
Imp2 expression is not restricted to spherogenic tumor-
initiating and self-renewing cells, but is also present in
adherent cultures that may represent the tumor bulk but
have lost tumorigenic potential. Importantly, themRNA-
binding repertoire of Imp2 was shared among normal
neural progenitors, gliomaspheres, and adherent GBM
cells. Moreover, its overexpression in normal astrocytes
increased their oxygen consumption, and, similar to
spherogenic cells, adherent GBM cells depleted of Imp2
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displayed decreased OCR. The function of Imp2 therefore
appears to be neither cell type- nor transformation-de-
pendent. However, whereas an OCR decrease in glioma-
spheres was accompanied by a chronic 20% drop in in-
tracellular ATP that significantly affected survival, ATP
levels in adherent cells remained unaltered in the face of
decreased OCR. These cells therefore appeared to be
resistant to OXPHOS inhibition and to have shifted their
energy dependence toward glycolysis, consistent with the
Warburg effect. The dichotomy between spherogenic and
adherent cells regarding their dependence on OXPHOS or
glycolysis was not related to the high oxygen and glucose
levels of in vitro culture, as it remained unaltered when
the cells were subjected to hypoxic, low-glucose condi-
tions that more closely reflect the primary tumor micro-
environment. Metabolic differences between primitive
GBM CSCs and more differentiated cells have been
reported by others (Wakimoto et al. 2009; Vlashi et al.
2011), supporting our observations that cells with CSC
features depend on OXPHOS. Importantly, these differ-
ences were also observed ex vivo on CSC subpopulations
freshly dissociated from surgically removed tumor spec-
imens. Whether dependence on OXPHOS can be gener-
alized to tumorigenic cell populations with CSC features,
irrespective of tumor type, remains to be explored.
Taken together, our observations provide new insight
into the function of Imp2 as a respiratory chain CIV
mRNA-binding protein and a putative CI chaperone that
regulates OXPHOS and appears to be critical for GBM
sphere-forming cell survival and function. These findings
may have important clinical implications, as the selec-
tive expression of Imp2 in GBM may render it a poten-
tially attractive novel therapeutic target for depletion of
tumorigenic cells with CSC features.
Materials and methods
Tumor samples, gliomaspheres, adherent cells, human
neural progenitor cell culture, clonogenic assays,
and sphere diameter measurement
Experimental procedures were performed as previously de-
scribed (Suva` et al. 2009). Briefly, surgical biopsies from three
GBM patients (in accordance with HUG protocol 04-113) were
dissociated to single-cell suspension and cultured in DMEM/F12
(Gibco), 20% BIT (Stem Cell Technologies), 10 ng/mL recombi-
nant human epidermal growth factor (EGF) (Invitrogen), 10 ng/
mL recombinant human basic fibroblast growth factor (FGF)
(Invitrogen), and 1% penicillin/streptomycin (Gibco). As previ-
ously described (Galli et al. 2004; Singh et al. 2004; Lee et al.
2006; Beier et al. 2007), nonadherent cellular spheroids obtained
in these growth conditions were considered as cultures enriched
for CSCs and were used for subsequent experiments. Glioma-
spheres were retained in culture for no longer than 15 passages,
and it has been reported that CSCs can be sustained in sphero-
genic cultures for up to 25 passages (Clement et al. 2010).
Adherent cell cultures were obtained by spheroid dissociation
and culture in serum-containing DMEM-F12 (Gibco) supple-
mented with 10% FBS (Gibco) and 1% penicillin/streptomycin
(Gibco). The human astrocyte cell line SVGp12 was cultured in
RPMI (Gibco) supplemented with 10% FBS (Gibco) and 1%
penicillin/streptomycin (Gibco). The human neural progenitor
cells hNP1 (Aruna Biomedical) were cultured according to the
provider’s protocol onMatrigel-coated plates in AB2 basal neural
medium supplemented with ANS neural medium supplement
(Aruna Biomedical), 50 mg/mL FGF (Invitrogen), 200 mM gluta-
mine (Gibco), 10 mg/mL LIF (Milipore), and 1% penicillin/
streptomycin (Gibco).
For clonogenic assays, disaggregated spheroids were plated as
single cells at a density of one cell per well in 96-well plates,
three plates per condition, and cultured for 2 wk in serum-free
medium.
Sphere diametermeasurementswere donewith ImageJ software.
For each condition, images of 50–100 spheres were analyzed.
Survival analysis
Imp2 expression in GBM samples stratified according to TCGA
criteria was obtained from the combined data set of Verhaak
et al. (2010). Samples were divided into ‘‘high’’ (top 50%) and
‘‘low’’ (bottom 50%) groups based on Imp2 expression. For
Kaplan-Meier survival analysis, only patients that had received
both chemotherapy and radiation therapy were considered, and
proneural samples were selected based on assignment from
Verhaak et al. (2010). All calculations were performed with the
R statistical computation package.
CD133 cell isolation
Surgical biopsies from six GBM patients were immediately
dissociated to single-cell suspensions with Brain Tumor Disso-
ciation Kit P (Miltenyi), according to the manufacturer’s pro-
tocol. Dead cell removal was performed on MACS columns
(Miltenyi), and subsequently, cell sorting was performed using a
CD133 Cell Isolation kit (Miltenyi).
Chemical compounds and treatments
Inhibition of OXPHOS was achieved by 1 mM rotenone (Sigma).
Inhibition of complex V ATPase was performed with 5 mg/mL
oligomycin. The lactate dehydrogenase inhibitor oxamic acid
was used at 25 mM to block glycolysis. Treatments were applied
for 72 h. For ATP content measurement, treatment time was
shortened to 0.5 h.
For mRNA degradation studies, 10 mg/mL actinomycin D
(Sigma) was added to cell growth medium. RNA was collected
after 0, 4, 8, and 12 h of treatment.
Imp2 knockdown and retroviral infection
shRNA sequences targeting Imp2 were sh1 sense strand (59-GA
TCCACCAAACTAGCCGAAGAGATTCAAGAGATCTCTTC
GGCTAGTTTGGTTTTTTTACGCGTG-39) and antisense strand
(59-AATTCACGCGTAAAAAAACCAAACTAGCCGAAGAGA
TCTCTTGAATCTCTTCGGCTAGTTTGGTG-39) and sh2 sense
strand (59-GATCCGCGGAAAGAACCATCACTGTTTCAAGA
GAACAGTGATGGTTCTTTCCGTTTTTTACGCGTG39) and
antisense strand (59-AATTCACGCGTAAAAAACGGAAAGAA
CCATCACTGTTCTCTTGAAACAGTGATGGTTCTTTCCG
CG-39).
Sense and antisense oligonucleotides were annealed to form
duplexes and inserted into the pSIREN-Retro Q retroviral vector
(BD Biosciences Clontech) according to the manufacturer’s
recommendations. Imp2 or control shRNA plasmids were trans-
fected into GP2 packaging cells to produce the virus used to
infect target gliomaspheres. Viral supernatant was concentrated
by ultracentrifugation using a SW28 rotor (Beckman Coulter)
at 19,500 rpm for 90 min. Concentrated virus was added to
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dissociated spheres. Forty-eight hours later, cells were selected
for puromycin (2 mg/mL) resistance for 5 d. The efficiency of
Imp2 depletion was verified by qRT–PCR and Western blot
analysis. All experiments with Imp2-depleted cells were per-
formed immediately after the end of the selection period.
Imp2 overexpression
The PCR product generated with the primers Fwd (59-GAAG
ATCTTCCCACCATGATGAACAAGCTTTACATC-39) and Rev
(59-CGGAATTCTCACTTGCTGCGCTGTGAGGCGACT-39) on
GBM CSC genomic DNA was cloned into the pMSCV_puro
vector (Clontech). The human immortalized astrocytic cell
line SVGp12 was infected with pMSCV_Imp2 or empty vector
containing virus according to standard protocols. Cells were
selected for puromycin (2 mg/mL) resistance for 7 d.
Rescue experiment
Spherogenic cells were infected with pMSCV_Imp2- or empty
vector-containing virus, selected for puromycin (2 mg/mL) re-
sistance for 5 d, dissociated, and transfected with Imp2 siRNA
(59-CACCTGACAGAATGAGACCTT-39) specific for the 39 UTR
mRNA region or ctrl siRNA. Seventy-two hours post-trans-
fection, the Imp2 protein expression level was determined, and
cells were subjected to OCR measurement.
NOD/SCID mouse xenotransplantation and survival analysis
The in vivo experiments were conducted as described previously
(Suva` et al. 2009). Intracranial injections of 500 cells (unless
indicated otherwise) from gliomaspheres at coordinates x = 2,
y = 0, and z = 2 relative to bregma point were performed with
a stereotactic apparatus (Kopf Instruments). The procedure was
approved by the Etat de Gene`ve, Service Ve´te´rinaire, authoriza-
tion number 1007/3337/2. Six NOD/SCID mice were used per
condition. Survival analysis significance was calculated with a
log-rank test.
Immunohistochemistry
Paraffin-embedded sections of gliomas and normal brains were
stained with mouse anti-human Imp2 antibody (1:50 dilution;
Abcam). Horseradish peroxidase (HRP) staining was performed
using biotin-conjugated rabbit anti-mouse IgG (Vector Laborato-
ries) and revealed with a DAKO DAB kit (DAKO).
Immunofluorescence
Gliomaspheres or adherent GBM cells were fixed with 4% PFA,
washed, permeabilized with 3% Triton X-100, incubated with
anti-Imp2 antibody (1:100, 0.5 mg/mL; Abcam) for 30 min fol-
lowed by donkey anti-mouse Alexa488 antibody (1:1300; Molec-
ular Probes), and mounted in 1:1000 DAPI in mounting medium
(ThermoShandon). Antibody specificity was compared with the
isotype-matched control antibody. Images were acquired with a
Leica SP5 AOBS confocal microscope at the Imaging Core Facility
of the University of Lausanne. The acquisition was performed in
sequential mode to avoid dye cross-talk. Three-dimensional re-
construction of sphere staining was done with Imaris software.
Paraffin-embedded sections of GBM and embryonal brains
were stained with anti-Imp2 (1:50; MBL Ribonomics), anti-
Nestin (1:200; Milipore), anti-GFAP (1:500; Dako), or anti-SSEA-1
(1:100; Stemgent) antibody. Secondary antibodies used were don-
key anti-rabbit Alexa488 (1:1300; Molecular Probes) and donkey
anti-mouse Alexa594 (1:1300; Molecular Probes), respectively.
FACS
Expression of CSC-associated cell surface markers was analyzed
by FACS. Single-cell suspensions were stained with single-
labeled antibody and analyzed in a FACScalibur apparatus
(Becton Dickinson). Antibodies used were anti-CD133/1-phyco-
erythrin antibody (AC133/1, 1:10; Miltenyi), isotype control
mouse IgG2b-phycoerythrin (1:10; Miltenyi), anti-SSEA1-FITC
(1:10; BD Pharmingen), and isotype control mouse IgMk-FITC
(1:10; BD Pharmingen).
qRT–PCR
qRT–PCR was performed as described previously (Suva` et al.
2009). For normalization, the 18S probe was used as the endog-
enous control. qRT–PCR primers are presented in Supplemental
Table 1.
Western blot
Western blotting was performed according to standard proce-
dures. The following antibodies were used: anti-Imp2 (0.5 mg/
mL; Abcam), anti-NDUFS3 (0.5 mg/mL; Abcam), anti-NDUFS7
(0.5 mg/mL; Abcam), anti-NDUF3 (0.5 mg/mL; Abcam), anti-
Cox7b (0.5 mg/mL; Abcam), anti-caspase 3 p20 (0.2 mg/mL; Santa
Cruz Biotechnology), anti-b-actin (1.65 mg/mL; Sigma), and anti-
a-tubulin (0.025 mg/mL; Calbiochem). Secondary antibodies
were HRP-conjugated goat anti-mouse (GE Healthcare), mouse
anti-rabbit (DAKO), and rabbit anti-goat (DAKO) antibodies.
Imp2 was detected as a doublet. However, no cross-reactivity
with Imp1 or Imp3 was found (data not shown).
Proliferation assay and cell cycle analysis
Proliferation was assessed with Cell Proliferation ELISA BrdU
colorimetric (Roche) according to the manufacturer’s protocol.
For cell cycle analysis, cells were resuspended in 10 ng/mL
propidium iodide with 1% IGEPAL, vortexed, incubated over-
night at 4°C, and analyzed by FACS.
Intact mitochondria isolation and proteinase K treatment
Intact mitochondria were isolated from 20 3 106 GBM CSCs
with Mitochondria Isolation Kit for Cultured Cells (Pierce). To
remove proteins from the mitochondrial surface, mitochondrial
pellets were resuspended in buffer C (Mitochondria Isolation Kit
for Cultured Cells, Pierce) and treated with 50 mg/mL proteinase
K (Sigma) for 30 min on ice and spun down at 10,000g for 10 min.
RIP-ChIP assay
We used 30 3 106 spherogenic or adherent cells per experiment.
Imp2-bound RNA immunoprecipitation was performed accord-
ing to the RiboCluster Profiler RIP assay kit protocol (MBL
Ribonomics). Eluted RNA was analyzed at the DNA Array
Facility, Lausanne, using Affymetrics Arrays. RIP-ChIP results
generated from three different primary cultures were compared.
Probe sets showing a false discovery rate of <0.05 and logarith-
mic fold changes of >2 in all three samples were subjected to
further analysis. Gene ontology annotations obtained for those
probes were considered as overrepresented when the P-value of
an exact one-tailed Fisher test was <0.00005.
RIP assay
Imp2-bound RIP was performed according to the RiboCluster
Profiler RIP assay kit protocol (MBL Ribonomics) from 20 3 106
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hNP1 cells and two spherogenic cell batches cultured in hypoxic
conditions for 5 d. Eluted RNA was analyzed by qRT–PCR.
Pull-down assay
Spherogenic cells (80 3 106) were suspended in PBS with a pro-
tease inhibitor cocktail (Roche), centrifuged, resuspended in 5
vol of RIP assay lysis buffer (without addition of DTT), and
sonicated for 10 sec. The lysate was centrifuged at 3500 rpm for 5
min at 4°C. Agarose protein-A beads (GE Healthcare), previously
washed with wash buffer from the RIP assay kit without DTT,
were added to the supernatants and discarded after 2 h of
preclearing. Incubationwith 20mg of anti-Imp2 (MBLRibonomics)
or isotype-matched control antibody was performed overnight at
4°C, followed by incubation with the beads for 4 h. The beads
were washed, and mass spectrometry analysis was performed at
the Protein Analysis Facility of Faculty of Biology and Medicine,
University of Lausanne.
PLA
Adherent GBM cells grown on 16-well glass chamber slides (Lab-
Tek) until confluence were transfected with a COX7b 39 UTR-
designed oligo RNA (59-TCATCCCAGCTGGTGTAATAATGA
ATTGTTTAAAAAACAGCTCATAATTGATGCCAAATTAAA
GCAC-39) or VSV oligo RNA, (59-ACATAAAAAGCTTTTTAA
CCAAGCAAGAATGAAGTATCGTATCTAATTAATTCCGAT
GATCAATATG-39), each containing a 59-terminal biotin tag, using
DOTAP reagent (Biontex) according to themanufacturer’s protocol.
Six hours post-transfection, cells were fixed with 4% PFA,
permeabilized with 0.3% Triton X-100 in PBS, and processed
according to the Duolink In Situ PLA assay protocol (Olink
Biosciences). Anti-Imp2 (1:100; Abcam) and anti-biotin (1:5000;
Pierce Thermo Scientific) antibodies were used. Reaction with-
out either anti-Imp2 or anti-biotin antibody provided controls.
Samples were analyzed with a Zeiss LSM 710 Quasar confocal
microscope.
MitoTracker assay
Cells were washed with PBS, resuspended in prewarmed medium
containing 250 nM MitoTracker Red CM-H2XRos (Molecular
Probes) or DMSO, and incubated for 30 min at 37°C. Cells were
then washed and resuspended in PBS and analyzed by FACS.
OCR/ECAR measurement
Twenty-thousand to 50,000 cells per well were seeded in XF24
cell culture microplates (Seahorse Bioscience). For each cell
type, five replicates were made. Measurements for spherogenic
cells were made immediately after sphere disruption and
viable cell counting (Trypan blue exclusion), and, following
the assay, cell viability was verified (Calcein AM staining [1:200,
2mg/mL; Calbiochem] analyzed by FACS). For adherent cells,
measurements were made 12–16 h after seeding, and uniformity
in cell proliferation was verified using a Cell Proliferation ELISA
BrdU colorimetric assay (Roche).
ATP content measurement
Gliomaspheres or adherent cells were disaggregated or detached,
respectively, and seeded in three replicates at 50,000 viable cells
per well in black-wall clear-bottom 96-well plates. Immediately
after plating cells, CellTiter-Glo reagent (Promega) was added,
and luminescence was measured in a SynergyMx instrument
(BioTek).
Citrate synthase activity measurement
Equal numbers of viable cells were lysed with Cell Lytic M
reagent (Cytrate Synthase Assay kit, Sigma), and samples were
prepared according to the manufacturer’s protocol. Calculations
of citrate synthase activity from sample absorbance were done as
described by the manufacturer.
MitoSOX assay
Superoxide production was assessed byMitoSOXRed (Molecular
Probes) staining. Cells were washed, resuspended in PBS con-
taining 5 mMMitoSOX Red or DMSO, and incubated for 30 min
at 37°C. Cells were then washed, resuspended in PBS, and
analyzed by FACS.
HNE protein adduct determination
Oxidative stress was assessed with OxiSelect HNE-His Ad-
duct ELISA kit (Cell Biolabs) according to the manufacturer’s
protocol.
BN-PAGE, in-gel activity assays,
and respiratory complex assembly
Mitochondrial extract preparation, Blue Native gel electropho-
resis, and in-gel activity for respiratory CI and CIV were
performed as described (Nijtmans et al. 2002). Briefly, spheres
disaggregated to single cells were resuspended in PBS with
protease inhibitors and lysed with an equal volume of cold
digitonin solution (8 mg/mL; Calbiochem). After 10 min of
incubation on ice and 5 min of centrifugation at 14,000 rpm at
4°C, the pellet was resuspended in 1.5 M aminocaproic acid and
50 mM Bis-Tris-HCl (pH 7) supplemented with 1.7% dodecyl-
maltoside (Invitrogen). After 5 min of incubation on ice and 5
min of centrifugation at 14,000 rpm at 4°C, the protein concen-
tration in the supernatant was measured, and 40 mg or 100 mg of
sample was loaded onto a native gel. For in-gel activity assays of
CI and CIV, gels were incubated overnight with 2 mM Tris-HCl
(pH 7.4), 0.1 mg/mL NADH (Roche), and 2.5 mg/mL nitro-
tetrazolium blue (Sigma), or 0.05% diaminobenzidine tetrahy-
drochloride (DAB), 20 mg/mL catalase (Sigma), 0.1% cytochrome
c (Sigma), and 7.5% sucrose in PBS, respectively. Respiratory
complex assembly was determined by post-BN-PAGE Western
blotting. BN-PAGE gels were blotted over a PVDF membrane in
40 mM Tris-HCl (pH 7) with 20 mM sodium acetate, 2 mM
EDTA, 20% methanol, and 0.05% SDS (from Bolt and Mahoney
1997) overnight at 30 V. To remove Coomassie stain from the
membrane, the blot was dried and rinsed with methanol prior to
blocking. Primary antibodies used were anti-NDUFS3 (0.5 mg/
mL, Abcam) and anti-ND2 (0.5 mg/mL; Abcam) for CI, or anti-
COX7b (0.25 mg/mL; Abcam) for CIV.
Mitochondria-bound and free polysome extraction
Experimental procedures were performed as previously de-
scribed (Sylvestre et al. 2003). SVGp12 cells stably overexpress-
ing Imp2 or control vector were trypsinized, incubated with 250
mg/mL cycloheximide for 15 min at 37°C, washed, and resus-
pended in extraction buffer (0.6 Mmannitol, 30 mMTris/HCl, at
pH 7.4, 5 mM MgOAc, 100 mM KCl [7.4 g], 1 g/L BSA, 5 mM
b-mercaptoethanol, 200 mg/mL cycloheximide, 500 mg/mL hep-
arin, protease inhibitor cocktail in DEPC-water). After addition
of 100 mg/mL digitonin and 4min of incubation on ice, cells were
disrupted in a glass homogenizer (cell lysis was verified under the
microscope) and spun at 2500 rpm for 7 min. Homogenization
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and centrifugation were repeated, and the homogenates were
centrifuged twice at 2500 rpm for 7 min. The obtained superna-
tant was centrifuged at 11,000 rpm for 30 min. The pellet
containing mitochondria with bound polysomes was washed
twice with the extraction buffer. The supernatant was used to
obtain free cytosolic polysomes by centrifugation over a sucrose
step gradient (2 M and 0.5 M sucrose in extraction buffer) at
25,000 rpm for 17 h. RNA was extracted from both polysome-
containing fractions (RNeasy kit, Qiagen). qRT–PCR was per-
formed according to standard procedures. Additional primers for
Nestin (Imp2-unrelated transcript; TaqMan probe), 12S (mito-
chondrial rRNA; control for equal mitochondrial purification
efficiency; Fwd [59-TAGCCCTAAACCTCAACAGT-39] and Rev
[59-TGCGCTTACTTTGTAGCCTTCAT-39]), andUCP2 (control
for mitochondria-bound polysomal transcripts; Fwd [59-CCCT
TGCCACTTCACTTCTG-39] and Rev [59-GAGAAAGGAGGG
CATGAACC-39]) were used. Relative transcript amounts were
normalized to 18S, then a ratio of transcript amount of free to
mitochondria-bound polysomes was calculated for control cells
and Imp2-overexpressing cells. The UCP2 ratio was set as
a cutoff, as this transcript should be enriched on mitochon-
dria-bound polysomes. Therefore, transcripts with ratios
below that of UCP2 are considered to be in higher numbers
on mitochondria-bound polysomes.
Statistical methods
Microarray gene expression data for nonmalignant brains and
different gliomas were obtained from Sun et al. (2006) (Gene
Expression Omnibus accession no. GSE4290). Data were nor-
malized with RMA, and probes corresponding to the same gene
were collapsed to the maximum value using the GenePattern
software package (Reich et al. 2006). T-test P-values for sample
comparisons were calculated using the R statistical software
package (http://www.r-project.org).
P-values were calculated with GraphPad Prism 5 software
using the statistical tests indicated in the figure legends.
Acknowledgments
We thank Keith Harshman (Genomic Technologies Facility,
Faculty of Biology and Medicine, University of Lausanne) for
performing themicroarray experiments, andManfredo Quadroni
(Protein Analysis Facility, Faculty of Biology and Medicine,
University of Lausanne) for the mass spectrometry analysis.
We also thankWhitney Quong, Claudio De Vito, Karine Baumer,
Benoıˆt Lhermitte, and Carlo Fusco for technical assistance and
discussions, and Sylviane Trepey, Jean-Christophe Stehle, and
Janine Holbeck for immunohistochemistry. This work was
supported by Swiss National Foundation (FNRS) grant 310030_
130350, NCCR Molecular Oncology, a MEDIC Foundation grant
to I.S., and Oncosuisse grant BIL-KFS-02590-02-2010 to M.S. P.P.
acknowledges funding from the Italian Association for Cancer
Research (AIRC). R.H.H. was supported by a Rubicon fellowship
from the Netherlands Organization for Scientific Research (NWO).
The work in the Auwerx laboratory was supported by grants of the
Ecole Polytechnique Fe´de´rale de Lausanne, Swiss National Science
Foundation, NIH (DK59820), the Velux Stiftung, and the European
Research Council Ideas program (Sirtuins; ERC-2008-AdG23118).
We thank all the members of the Auwerx laboratory for inspiring
discussions.
References
Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G,
Carmona MA, Prieto-Sanchez RM, Barba I, Martinez-Saez E,
Prudkin L, et al. 2010. TGF-b receptor inhibitors target the
CD44(high)/Id1(high) glioma-initiating cell population in
human glioblastoma. Cancer Cell 18: 655–668.
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB,
Dewhirst MW, Bigner DD, Rich JN. 2006. Glioma stem cells
promote radioresistance by preferential activation of the
DNA damage response. Nature 444: 756–760.
Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J,
Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP.
2007. CD133+ and CD133 glioblastoma-derived cancer
stem cells show differential growth characteristics and
molecular profiles. Cancer Res 67: 4010–4015.
Bolt MW, Mahoney PA. 1997. High-efficiency blotting of pro-
teins of diverse sizes following sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. Anal Biochem 247:
185–192.
Boudoukha S, Cuvellier S, Polesskaya A. 2010. Role of the RNA-
binding protein IMP-2 in muscle cell motility. Mol Cell Biol
30: 5710–5725.
Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner
B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. 2007. A
perivascular niche for brain tumor stem cells. Cancer Cell
11: 69–82.
Carroll J, Fearnley IM, Shannon RJ, Hirst J, Walker JE. 2003.
Analysis of the subunit composition of complex I from
bovine heart mitochondria. Mol Cell Proteomics 2: 117–126.
Carroll J, Fearnley IM, Skehel JM, Shannon RJ, Hirst J, Walker
JE. 2006. Bovine complex I is a complex of 45 different
subunits. J Biol Chem 281: 32724–32727.
Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW,
Hambardzumyan D, Holland EC. 2010. Perivascular nitric
oxide activates notch signaling and promotes stem-like char-
acter in PDGF-induced glioma cells.Cell Stem Cell 6: 141–152.
Christiansen J, Kolte AM, Hansen TO, Nielsen FC. 2009. IGF2
mRNA-binding protein 2: Biological function and putative
role in type 2 diabetes. J Mol Endocrinol 43: 187–195.
Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i
Altaba A. 2007. HEDGEHOG–GLI1 signaling regulates hu-
man glioma growth, cancer stem cell self-renewal, and
tumorigenicity. Curr Biol 17: 165–172.
Clement V, Marino D, Cudalbu C, Hamou M-F, Mlynarik V, de
Tribolet N, Dietrich P-Y, Gruetter R, Hegi ME, Radovanovic
I. 2010. Marker-independent identification of glioma-initiat-
ing cells. Nat Methods 7: 224–228.
Clevers H. 2011. The cancer stem cell: Premises, promises and
challenges. Nat Med 17: 313–319.
Currle DS, Gilbertson RJ. 2008. The niche revealed. Cell Stem
Cell 3: 234–236.
Dai N, Rapley J, Angel M, Yanik MF, Blower MD, Avruch J. 2011.
mTOR phosphorylates IMP2 to promote IGF2 mRNA trans-
lation by internal ribosomal entry. Genes Dev 25: 1159–1172.
Dean M, Fojo T, Bates S. 2005. Tumour stem cells and drug
resistance. Nat Rev Cancer 5: 275–284.
Dimitriadis E, Trangas T, Milatos S, Foukas PG, Gioulbasanis I,
Courtis N, Nielsen FC, Pandis N, Dafni U, Bardi G, et al.
2007. Expression of oncofetal RNA-binding protein CRD-BP/
IMP1 predicts clinical outcome in colon cancer. Int J Cancer
121: 486–494.
Ezhilarasan R, Mohanam I, Govindarajan K, Mohanam S. 2007.
Glioma cells suppress hypoxia-induced endothelial cell apopto-
sis and promote angiogenic process. Int J Oncol 30: 701–707.
Fernandez-Vizarra E, Tiranti V, Zeviani M. 2009. Assembly of
the oxidative phosphorylation system in humans: What we
have learned by studying its defects. Biochim Biophys Acta
1793: 200–211.
Frank NY, Schatton T, Frank MH. 2010. The therapeutic promise
of the cancer stem cell concept. J Clin Invest 120: 41–50.
Janiszewska et al.
1942 GENES & DEVELOPMENT
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S,
Fiocco R, Foroni C, Dimeco F, Vescovi A. 2004. Isolation and
characterization of tumorigenic, stem-like neural precursors
from human glioblastoma. Cancer Res 64: 7011–7021.
Go¨rlach A, Acker, H. 1994. pO2- and pH-gradients in multicel-
lular spheroids and their relationship to cellular metabolism
and radiation sensitivity of malignant human tumor cells.
Biochim Biophys Acta 1227: 105–112.
Hammer NA, Hansen TO, Byskov AG, Rajpert-De Meyts E,
Grondahl ML, Bredkjaer HE, Wewer UM, Christiansen J,
Nielsen FC. 2005. Expression of IGF-II mRNA-binding pro-
teins (IMPs) in gonads and testicular cancer. Reproduction
130: 203–212.
Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next
generation. Cell 144: 646–674.
Himoto T, Kuriyama S, Zhang JY, Chan EK, Kimura Y, Masaki
T, Uchida N, Nishioka M, Tan EM. 2005a. Analyses of
autoantibodies against tumor-associated antigens in patients
with hepatocellular carcinoma. Int J Oncol 27: 1079–1085.
Himoto T, Kuriyama S, Zhang JY, Chan EK, Nishioka M, Tan
EM. 2005b. Significance of autoantibodies against insulin-
like growth factor II mRNA-binding proteins in patients with
hepatocellular carcinoma. Int J Oncol 26: 311–317.
Joo KM, Kim SY, Jin X, Song SY, Kong D-S, Lee JI, Jeon JW, Kim
MH, Kang BG, Jung Y, et al. 2008. Clinical and biological
implications of CD133-positive and CD133-negative cells in
glioblastomas. Lab Invest 88: 808–815.
Jose C, Bellance N, Rossignol R. 2011. Choosing between
glycolysis and oxidative phosphorylation: A tumor’s dilemma?
Biochim Biophys Acta 6: 552–561.
Kobel M, Weidensdorfer D, Reinke C, Lederer M, Schmitt WD,
Zeng K, Thomssen C, Hauptmann S, Huttelmaier S. 2007.
Expression of the RNA-binding protein IMP1 correlates
with poor prognosis in ovarian carcinoma. Oncogene 26:
7584–7589.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-
Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. 1994.
A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature 367: 645–648.
Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM,
Pastorino S, Purow BW, Christopher N, Zhang W, et al.
2006. Tumor stem cells derived from glioblastomas cultured
in bFGF and EGF more closely mirror the phenotype and
genotype of primary tumors than do serum-cultured cell
lines. Cancer Cell 9: 391–403.
Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q,
Cao Y, Lathia J, McLendon RE, et al. 2009. Hypoxia-in-
ducible factors regulate tumorigenic capacity of glioma stem
cells. Cancer Cell 15: 501–513.
Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J,
Junker M, Oefner PJ, Bogdahn U, Wischhusen J, et al. 2010.
Transcriptional profiles of CD133+ and CD133 glioblastoma-
derived cancer stem cell lines suggest different cells of origin.
Cancer Res 70: 2030–2040.
Louis DN. 2006. Molecular pathology of malignant gliomas.
Annu Rev Pathol 1: 97–117.
Magee JA, Piskounova E, Morrison SJ. 2012. Cancer stem cells:
Impact, heterogeneity, and uncertainty.Cancer Cell 21: 283–296.
Mason MG, Nicholls P, Wilson MT, Cooper CE. 2006. Nitric
oxide inhibition of respiration involves both competitive
(heme) and noncompetitive (copper) binding to cytochrome c
oxidase. Proc Nat Acad Sci 103: 708–713.
Murray J, Zhang B, Taylor SW, Oglesbee D, Fahy E, Marusich
MF, Ghosh SS, Capaldi RA. 2003. The subunit composition
of the human NADH dehydrogenase obtained by rapid one-
step immunopurification. J Biol Chem 278: 13619–13622.
Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH,
Wewer UM, Nielsen FC. 1999. A family of insulin-like
growth factor II mRNA-binding proteins represses transla-
tion in late development. Mol Cell Biol 19: 1262–1270.
Nijtmans LG, Henderson NS, Holt IJ. 2002. Blue Native elec-
trophoresis to study mitochondrial and other protein com-
plexes. Methods 26: 327–334.
Rehling P, Brandner K, Pfanner N. 2004. Mitochondrial import
and the twin-pore translocase. Nat Rev Mol Cell Biol 5: 519–
530.
Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP.
2006. GenePattern 2.0. Nat Genet 38: 500–501.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M,
Peschle C, De Maria R. 2007. Identification and expansion of
human colon-cancer-initiating cells. Nature 445: 111–115.
Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G,
Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, et al.
2010. Tumour vascularization via endothelial differentiation
of glioblastoma stem-like cells. Nature 468: 824–828.
Rong Y, Durden DL, Van Meir EG, Brat DJ. 2006. ‘Pseudopali-
sading’ necrosis in glioblastoma: A familiar morphologic
feature that links vascular pathology, hypoxia, and angio-
genesis. J Neuropathol Exp Neurol 65: 529–539.
Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen
H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, et al. 2007.
Genome-wide association analysis identifies loci for type 2
diabetes and triglyceride levels. Science 316: 1331–1336.
Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL,
Erdos MR, Stringham HM, Chines PS, Jackson AU, et al.
2007. A genome-wide association study of type 2 diabetes in
Finns detects multiple susceptibility variants. Science 316:
1341–1345.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T,
Henkelman RM, Cusimano MD, Dirks PB. 2004. Identifica-
tion of human brain tumour initiating cells. Nature 432:
396–401.
Son MJ, Woolard K, Nam D-H, Lee J, Fine HA. 2009. SSEA-1 is
an enrichment marker for tumor-initiating cells in human
glioblastoma. Cell Stem Cell 4: 440–452.
Suissa M, Schatz G. 1982. Import of proteins into mitochondria.
Translatable mRNAs for imported mitochondrial proteins
are present in free as well as mitochondria-bound cytoplas-
mic polysomes. J Biol Chem 257: 13048–13055.
Sun L, Hui A-M, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S,
Passaniti A, Menon J, Walling J, Bailey R, et al. 2006.
Neuronal and glioma-derived stem cell factor induces angio-
genesis within the brain. Cancer Cell 9: 287–300.
Sutherland RM. 1998. Tumor hypoxia and gene expression—
implications for malignant progression and therapy. Acta
Oncol 37: 567–574.
Suva` M-L, Riggi N, Janiszewska M, Radovanovic I, Provero P,
Stehle J-C, Baumer K, Le Bitoux M-A, Marino D, Cironi L,
et al. 2009. EZH2 is essential for glioblastoma cancer stem
cell maintenance. Cancer Res 69: 9211–9218.
Sylvestre J, Margeot A, Jacq C, Dujardin G, Corral-Debrinski M.
2003. The role of the 39 untranslated region in mRNA sorting
to the vicinity of mitochondria is conserved from yeast to
human cells. Mol Biol Cell 14: 3848–3856.
Vander Heiden MG, Cantley LC, Thompson CB. 2009. Un-
derstanding the Warburg effect: The metabolic requirements
of cell proliferation. Science 324: 1029–1033.
Vaupel P, Kallinowski F, Okunieff P. 1989. Blood flow, oxygen
and nutrient supply, and metabolic microenvironment of
human tumors: A review. Cancer Res 49: 6449–6465.
Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson
MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. 2010.
Imp2 in glioblastoma cancer stem cells
GENES & DEVELOPMENT 1943
Integrated genomic analysis identifies clinically relevant
subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98–110.
Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou
M, Popescu R, Della Donna L, Evers P, Dekmezian C, et al.
2011. Metabolic state of glioma stem cells and nontumori-
genic cells. Proc Natl Acad Sci 108: 16062–16067.
Vogel RO, Smeitink JAM, Nijtmans LGJ. 2007. Human mito-
chondrial complex I assembly: A dynamic and versatile
process. Biochim Biophys Acta 1767: 1215–1227.
Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M,
Kuroda T, Stemmer-Rachamimov A, Shah K, Liu T-C, et al.
2009. Human glioblastoma-derived cancer stem cells: Estab-
lishment of invasive glioma models and treatment with
oncolytic herpes simplex virus vectors. Cancer Res 69:
3472–3481.
Wakimoto H, Mohapatra G, Kanai R, Curry WT, Yip S, Nitta M,
Patel AP, Barnard ZR, Stemmer-Rachamimov AO, Louis
DN, et al. 2012. Maintenance of primary tumor phenotype
and genotype in glioblastoma stem cells. Neuro-oncol 14:
132–144.
Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE,
Geber A, Fligelman B, Leversha M, Brennan C, Tabar V. 2010.
Glioblastoma stem-like cells give rise to tumour endothe-
lium. Nature 468: 829–833.
Yaniv K, Yisraeli JK. 2002. The involvement of a conserved
family of RNA binding proteins in embryonic development
and carcinogenesis. Gene 287: 49–54.
Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: From growth
signal integration to cancer, diabetes and ageing. Nat Rev
Mol Cell Biol 12: 21–35.
Janiszewska et al.
1944 GENES & DEVELOPMENT
